Novel biomarkers added to movement disorders profile: Andrew McKeon, M.B., B.Ch., M.D.
Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' expanded movement disorders panel better identifies autoimmune conditions to guide appropriate treatment.
Audio is streamed directly from the publisher (media.transistor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
(00:32)
Can you tell our audience a little bit about yourself and your role here at Mayo Clinic?
(01:29)
Can you tell our listeners a little bit about the disease state when we talk about autoimmune or paraneoplastic movement disorders?
(02:37)
Are we seeing an increased prevalence of autoimmune movement disorders?
(04:00)
Can you give our listeners an overview of what's going to be launched here in January?
(06:56)
What other antibodies are particularly important in this phenotype?
(10:01)
How does the kelch-like protein 11 phenotype manifest in this disorder?
(10:49)
Are there any antibodies in the autoimmune neurology space that would not need to be evaluated for in patients that present with some sort of movement disorder?
(11:18)
Which patients should have this testing and when should it be performed?
(12:55)
When should Mayo Clinic Laboratories' stiff person evaluation and standalone glycine receptor tests be used, and in what order?
(14:40)
Is the movement disorder evaluation the right first choice when the patient presentation is less typical and includes ataxia?
(16:42)
Can physicians order the glycine receptor standalone test to fully evaluate the spectrum of antibodies?
(18:39)
How does the evaluation impact patient care?
(20:12)
Have these new antibodies been shown to be immunotherapy-responsive?
(20:27)
Is there a key takeaway with the launch of these new antibodies in the movement disorder evaluation?